NEW YORK (GenomeWeb) – European firms Scienion and Grenier Bio-One today announced a collaboration to co-develop rapid, multiplexed diagnostic tests.
The partners said in a statement they would develop new tests for human pathogens that will yield test results within 75 minutes.
Financial and other details of the agreement were not disclosed.
The deal brings together Scienion's sciFlexarrayer liquid handling technology and Grenier's PCR-based Genspeed pathogen detection platform. Kremsmünster, Austria-based Grenier has already launched a methicillin-resistant Staphylococcus aureus test, the Genspeed MRSA.
The agreement is the latest in a string of technology partnerships for Berlin-based Scienion this year. In September, the firm partnered with Australian firm Axxin to develop a multiplexed microarray analysis system. In July, it partnered with Australian reagent maker Anteo Technologies to improve the shelf life of protein microarrays. And in June, Scienion agreed to integrate sciFlexarrayer into QuantuMDx's nanowire array technology and commercialize the biosensor.